Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
about
Acute myeloid leukemia in the older adultsPharmacological treatment options for mast cell activation diseaseMidostaurin: an emerging treatment for acute myeloid leukemia patients'Acute myeloid leukemia: a comprehensive review and 2016 update'Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Emerging therapies for acute myeloid leukemia.The Future of Targeting FLT3 Activation in AML.Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Midostaurin for the treatment of acute myeloid leukemia.Hypomethylating Agents as a Therapy for AML.Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Midostaurin: First Global Approval.Molecular targeting in acute myeloid leukemiaMidostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Precision therapy for acute myeloid leukemia.Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.Clinical use of FLT3 inhibitors in acute myeloid leukemia
P2860
Q26740584-483DA885-0980-40C7-8CBE-5F15ADD6758AQ26748784-D54DF4A7-6E71-49CF-8574-7F942CCA2143Q26749271-86A41029-497C-40FA-801E-DC8B855397B9Q28072539-D193A91E-21FF-4EA9-BE28-317AD648FF19Q30313903-4E1D75F0-2F6F-4F53-AEB2-02C26E0569FFQ33442949-0D0CD01B-5F03-4A9B-9D87-0FFA427FBB7DQ33576363-5C401574-C30E-4D88-B92F-B8BE7EBA83F6Q34555386-9BFEF45D-CA24-49F4-85D3-273481F5C53EQ35016157-992104E5-9DA8-403F-87A5-71A16781D80CQ35750567-8A455349-084A-4AC2-AD40-0F3E3A339B82Q35857472-1269398E-A88D-4DA3-99A3-8713B0E2FD08Q38664735-8E68F158-8405-47C9-BB1E-197DC231CCD5Q38671401-EDDA2EC3-6D6C-4696-A1BA-0C24FA5EC735Q38911864-24138EDE-D273-4E55-998E-C2659587444FQ38913785-E9FEA328-8D8F-4797-BDAC-B1EE09862EADQ38961023-E5405336-B87A-4A5F-8724-FDDD6FC3B85AQ39045977-6C1FB547-1E8E-4E81-97F8-7AE21B7C0E40Q39175665-D10C5098-EAF2-4A91-9240-4E97D59D9682Q39371391-70E16CF8-4D96-4721-8121-9673719E0B61Q41558732-AAF7C981-7CA7-4266-875C-E5F36C404F67Q42376734-99B5DCF9-6ED4-4D22-8F76-8A3286C02365Q46210383-963B93F8-BF5B-4D93-8442-EF69AFFEB123Q47439297-B23199A5-D4A6-49EA-80AE-8D27DD66FE3FQ47727992-942D15C4-2786-40D5-A6D6-7DD8585B1219Q47741553-32FCA932-363A-4FB9-AC30-537582C5E96DQ47877035-23F7E87C-95D9-4ED2-B6FF-FA8778E14BFAQ47965108-4A711A72-F870-4225-802E-6C7168B8723EQ49534332-03496D93-D78D-4B7B-9BEC-92C1EBCEF008Q49614743-4165449A-87C2-46B1-8BA5-DD4FE36A927EQ54160284-B69D5726-2FA7-48C6-AF32-BD5FF74128F1Q58558233-4294EEB5-8FBA-455D-B231-71141C60435F
P2860
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase I/II trial of the combin ...... and myelodysplastic syndrome.
@ast
Phase I/II trial of the combin ...... and myelodysplastic syndrome.
@en
type
label
Phase I/II trial of the combin ...... and myelodysplastic syndrome.
@ast
Phase I/II trial of the combin ...... and myelodysplastic syndrome.
@en
prefLabel
Phase I/II trial of the combin ...... and myelodysplastic syndrome.
@ast
Phase I/II trial of the combin ...... and myelodysplastic syndrome.
@en
P2093
P2860
P50
P356
P1476
Phase I/II trial of the combin ...... and myelodysplastic syndrome.
@en
P2093
Aziz Nazha
Mark Levis
Menda Durand
Naval Daver
Paolo Strati
Trivikram Rajkhowa
P2860
P304
P356
10.1002/AJH.23924
P50
P577
2015-03-02T00:00:00Z